Lung adenocarcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells. There is a male predilection with a male to female ratio of 2:1. Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding. If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever. Tobacco smoke is a known risk factor.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Lung adenocarcinoma
- Therapeutic area
- Oncology
- lung adenocarcinoma
- adenocarcinoma of lung
- adenocarcinoma of the lung
- lung adenocarcinoma
- non-small cell lung adenocarcinoma
- Severity
- Severe
- Oncology
- Pulmonology
- MONDO ID
- MONDO:0005061
- Parent condition
- MONDO:0004970
Related records
Broader conditions (23)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Glandular cell neoplasm
- Human disease
- Lower respiratory tract disorder
- Lung cancer
- Lung carcinoma
- Lung disorder
- Lung neoplasm
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Non-small cell lung carcinoma
- Respiratory system cancer
Narrower conditions (16)
- Acinar lung adenocarcinoma
- Bronchus mucoepidermoid carcinoma
- Lung adenocarcinoma in situ
- Lung adenoid cystic carcinoma
- Lung colloid adenocarcinoma
- Lung combined type small cell adenocarcinoma
- Lung occult adenocarcinoma
- Lung signet ring cell carcinoma
- Minimally invasive lung adenocarcinoma
- Mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma
- Mucinous bronchioloalveolar adenocarcinoma
- Nonmucinous bronchioloalveolar adenocarcinoma
- Papillary lung adenocarcinoma
- Pulmonary mucoepidermoid carcinoma
- Solid adenocarcinoma with mucin production
- Well-differentiated fetal adenocarcinoma of the lung
Trials (413)
- 18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
- A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
- A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
- A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
- A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
- A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
- A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
- A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
- A Single-arm Exploratory Study of Neoadjuvant Therapy
- A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
- A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
- A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
- A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Drugs in development (62)
- Albumin human Phase 2
- Aldesleukin Phase 1
- Aspirin Early phase 1
- Auranofin Phase 1
- AXL-1717 Phase 2
- Bemcentinib Phase 2
- Berberine Phase 2
- Bevacizumab Phase 3
- Camrelizumab Phase 2
- Carboplatin Phase 3
- Catequentinib Phase 2
- Certolizumab Phase 1
- Cetuximab Phase 2
- Cisplatin Phase 3
- Cixutumumab Phase 2
- Crizotinib Phase 3
- Cyclophosphamide Phase 1
- Dimesna Phase 2
- Docetaxel Phase 3
- Durvalumab Phase 2